Stepanova, Maria
Nader, Fatema
Bureau, Christophe
Adebayo, Danielle
Elkrief, Laure
Valla, Dominique
Peck-Radosavljevic, Markus
McCune, Anne
Vargas, Victor
Simon-Talero, Macarena
Cordoba, Juan
Angeli, Paolo
Rossi, Silvia
MacDonald, Stewart
Capel, Jeroen
Jalan, Rajiv
Younossi, Zobair M.
Funding for this research was provided by:
Sequana Medical
Article History
Accepted: 14 February 2018
First Online: 19 February 2018
Compliance with ethical standards
:
: ZMY is a consultant or advisory board of Abbvie, Intercept, Gilead Sciences, Salix, GSK, BMS, Allergan, Sanofi, and Novo Nordisk. RJ has research collaborations with Ocera, and Yaqrit, consults for Ocera and Yaqrit, and has received speaking and consultation fees from Sequana. RJ is the founder of Yaqrit Limited, which is developing UCL inventions for treatment of patients with cirrhosis. LE had received funding from Sequana for reporting of the data into the CRF for this study. DV received an honorarium from Sequana Medical for this clinical study, is a consultant on the Liver Safety Committee of Laboratoires Servier, and has provided teaching services for Gilead Sciences. PA is a member of the Sequana Medical AG Advisory Board, the LAT Pharma LLC Advisory Board, and the Gilead Advisory Board in Italy. Other co-authors have indicated that they have no potential conflicts of interest to disclose.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.